期刊
FREE RADICAL BIOLOGY AND MEDICINE
卷 88, 期 -, 页码 18-29出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.freeradbiomed.2015.05.041
关键词
X-linked adrenoleukodystrophy; Oxidative damage; Mitochondrial dysfunction; Peroxisome; Very long-chain fatty acids; Proteasome; Autophagy
资金
- European Leukodystrophy Association [ELA2012-033C1]
- Spanish Institute for Health Carlos III [FIS PI11/01043, FIS PI14/00410, FIS ICI14/00076, CP11/00080]
- Hesperia Fundation
- Autonomous Government of Catalonia [2009SGR85, 2014SGR1430]
- ICREA Funding Source: Custom
Peroxisomal and mitochondrial malfunction, which are highly intertwined through redox regulation, in combination with defective proteostasis, are hallmarks of the most prevalent multifactorial neurodegenerative diseases including Alzheimer's (AD) and Parkinson's disease (PD)-and of the aging process, and are also found in inherited conditions. Here we review the interplay between oxidative stress and axonal degeneration, taking as groundwork recent findings on pathomechanisms of the peroxisomal neurometabolic disease adrenoleukodystrophy (X-ALD). We explore the impact of chronic redox imbalance caused by the excess of very long-chain fatty acids (VLCFA) on mitochondrial respiration and biogenesis, and discuss how this impairs protein quality control mechanisms essential for neural cell survival, such as the proteasome and autophagy systems. As consequence, prime molecular targets in the pathogenetic cascade emerge, such as the SIRT1/PGC-1 alpha axis of mitochondrial biogenesis, and the inhibitor of autophagy mTOR. Thus, we propose that mitochondria-targeted antioxidants; mitochondrial biogenesis boosters such as the antidiabetic pioglitazone and the SIRT1 ligand resveratrol; and the autophagy activator temsirolimus, a derivative of the mTOR inhibitor rapamycin, hold promise as disease-modifying therapies for X-ALD. (C) 2015 The Authors. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据